UK-based cannabis medicine company Celadon Pharmaceuticals has announced the appointment of Jonathan Turner as Chief Financial Officer of the group.
Turner will start a phased transition into his role from November 2022 and will join the company on a full-time basis from February 2023, when will be appointed to the board.
Turner joins from FTSE250-listed Oxford Instruments plc, where he has been Group Director of Accounting, Tax and Treasury since September 2020, and a Divisional Finance Director for the three years before that.
During this time, he has worked closely with the Oxford Instruments plc’s CFO and has been responsible for internal and external financial reporting, and developing and maintaining financial and operational systems.
Prior to this, Turner was also Group Company Secretary and Head of Tax and Treasury for FTSE-listed Synergy Health plc and Finance Director for NYSE listed STERIS plc, following its acquisition of Synergy.
Jonathan is a Chartered Accountant and Associate Member of the Association of Corporate Treasurers and was previously a Senior Manager at EY, where he worked from 2003 until 2010, and originally qualified at Smith & Williamson.
CEO of Celadon, James Short, said: “We are delighted to welcome Jonathan to the Group.
“His extensive experience operating within technology, manufacturing and scientific research industries will be important as Celadon continues to advance its position as a leading UK provider of breakthrough cannabis-based medicines.”
Turner succeeds Katie Long, who is returning to her role within Tessera Investment Management Limited, having established and led Celadon’s finance function over the previous year and during the company’s AIM IPO.
Katie will continue to provide support to the Company through to the commencement of Jonathan’s appointment on a full time basis, and will step down from the Board at that time.
“The Board would like to take this opportunity to thank Katie for her invaluable contribution since joining Celadon in February 2021, which has been a pivotal time in the Company’s development,” said Short.
“We wish her well on her return to Tessera.”